Published in Proc Natl Acad Sci U S A on November 29, 2004
Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC (NA_00092076) | NCT02259621
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma | NCT03918252
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer | NCT04019964
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 6.80
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia (2006) 3.54
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature (2011) 3.22
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest (2014) 3.06
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat (2014) 2.61
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood (2009) 2.54
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol (2013) 2.50
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol (2015) 2.30
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 2.25
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A (2006) 2.24
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res (2012) 2.23
The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry. Cancer Prev Res (Phila) (2015) 2.17
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med (2016) 2.16
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev (2011) 2.02
PD-1 as a potential target in cancer therapy. Cancer Med (2013) 1.98
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res (2008) 1.97
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 1.90
NFATc1 regulates PD-1 expression upon T cell activation. J Immunol (2008) 1.81
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res (2014) 1.79
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther (2015) 1.73
Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med (2012) 1.71
FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer (2008) 1.63
Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget (2015) 1.62
PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol (2014) 1.58
Harnessing the immune system to treat cancer. J Clin Invest (2007) 1.57
Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol (2007) 1.55
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A (2015) 1.54
Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology (2012) 1.48
PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother (2011) 1.47
Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov (2013) 1.46
External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer (2008) 1.45
Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One (2013) 1.44
Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev (2009) 1.44
PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene (2008) 1.41
Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res (2011) 1.38
B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS One (2013) 1.38
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunol Res (2015) 1.35
Cancer immunotherapy: the beginning of the end of cancer? BMC Med (2016) 1.32
Immunoregulatory role of B7-H1 in chronicity of inflammatory responses. Cell Mol Immunol (2006) 1.30
Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol (2011) 1.28
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol (2009) 1.28
B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol (2008) 1.25
Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther (2015) 1.23
Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res (2014) 1.23
Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer (2014) 1.22
At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol (2013) 1.21
Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res (2008) 1.21
The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia (2014) 1.18
Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer (2008) 1.16
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res (2014) 1.15
B7-h3 and its role in antitumor immunity. Clin Dev Immunol (2010) 1.14
Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res (2010) 1.14
Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies. BJU Int (2009) 1.13
Prostate cancer immunotherapy. Clin Cancer Res (2011) 1.11
B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer. Int J Clin Exp Pathol (2014) 1.10
TLR-mediated induction of negative regulatory ligands on dendritic cells. J Mol Med (Berl) (2008) 1.09
The complex role of B7 molecules in tumor immunology. Trends Mol Med (2008) 1.09
PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunol Res (2015) 1.08
A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma. Hum Genet (2013) 1.08
B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol (2014) 1.07
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut (2016) 1.06
Role of PD-L1 and PD-L2 in allergic diseases and asthma. Allergy (2010) 1.06
B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. Head Neck Pathol (2012) 1.05
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget (2015) 1.04
Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis. Int J Clin Exp Med (2015) 1.04
VISTA is an immune checkpoint molecule for human T cells. Cancer Res (2014) 1.03
Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer (2015) 1.03
Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. Immunotherapy (2014) 1.02
Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res (2014) 1.01
Immunotherapeutic strategies in kidney cancer--when TKIs are not enough. Nat Rev Clin Oncol (2009) 1.01
Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. Int J Clin Exp Pathol (2015) 1.00
The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells. Oncoimmunology (2013) 0.99
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some. Front Immunol (2015) 0.98
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res (2015) 0.98
B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence. J Urol (2008) 0.98
A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. Int J Mol Sci (2016) 0.97
Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. J Vis Exp (2013) 0.97
PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. Br J Cancer (2014) 0.97
Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. Ther Adv Urol (2016) 0.97
Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol (2012) 0.96
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol (2016) 0.95
Tissue biomarkers in renal cell carcinoma: issues and solutions. Cancer (2009) 0.95
Immunotherapy for prostate cancer: an emerging treatment modality. Urol Clin North Am (2010) 0.94
Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res (2011) 0.93
Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res (2014) 0.92
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res (2015) 0.92
Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One (2015) 0.90
Inhibitory costimulation and anti-tumor immunity. Semin Cancer Biol (2007) 0.90
Contemporary Treatment of Metastatic Renal Cell Carcinoma. Oncol Rev (2016) 0.90
PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget (2016) 0.90
Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol (2015) 0.89
Targeted therapy for renal cell carcinoma: The next lap. J Carcinog (2014) 0.89
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med (1999) 16.91
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res (2004) 5.59
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
The Heidelberg classification of renal cell tumours. J Pathol (1997) 5.36
The changing natural history of renal cell carcinoma. J Urol (2001) 4.72
B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity (2004) 4.60
CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol (2002) 4.48
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res (2003) 3.96
Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer (1997) 3.85
Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol (2003) 3.66
Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res (2001) 3.51
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 3.38
Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol (1998) 2.49
B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med (Berl) (2003) 2.48
Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res (2003) 2.27
Renal cell carcinoma. JAMA (2004) 2.19
Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int (1999) 2.19
T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res (1993) 1.98
Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest (2003) 1.87
Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol (2002) 1.82
The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer (2003) 1.58
Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol (2004) 1.42
Surgery of renal cell carcinoma. Urol Clin North Am (1993) 1.20
Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer (1995) 1.17
Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol (1997) 1.16
Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression. Oncogene (2003) 1.15
Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res (1999) 1.09
Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst (1994) 1.03
Prognostic value of ploidy and proliferation markers in renal cell carcinoma. Cancer (1996) 1.00
T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary report. Cancer Res (1994) 0.98
Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma. Crit Rev Oncol Hematol (2003) 0.97
Immunotherapy for urological malignancies. J Urol (2004) 0.96
Expression of cadherin-6 as a novel diagnostic tool to predict prognosis of patients with E-cadherin-absent renal cell carcinoma. Clin Cancer Res (1998) 0.94
Practice and progress in kidney cancer: methodology for novel drug development. J Urol (2004) 0.89
Costimulation-based immunotherapy for head and neck cancer. Curr Treat Options Oncol (2004) 0.89
Pro-inflammatory and T cell inhibitory cytokines are secreted at high levels in tumor cell cultures of human renal cell carcinoma. Eur Urol (1999) 0.89
Defective granzyme B gene expression and lytic response in T lymphocytes infiltrating human renal cell carcinoma. J Immunother (1997) 0.88
The use of ex vivo-activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study. Semin Urol (1993) 0.86
Significance of conventional and new prognostic factors for locally confined renal cell carcinoma. Cancer (1995) 0.86
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Guideline for management of the clinical T1 renal mass. J Urol (2009) 8.26
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21
Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol (2008) 8.17
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65
Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol (2008) 5.30
Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol (2007) 5.24
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res (2005) 4.94
B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity (2004) 4.60
Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med (2002) 4.18
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res (2003) 3.96
Pelvic lymph node dissection in prostate cancer. Eur Urol (2009) 3.93
Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol (2004) 3.92
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med (2006) 3.75
Every minute counts when the renal hilum is clamped during partial nephrectomy. Eur Urol (2010) 3.71
Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila) (2009) 3.70
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol (2003) 3.66
53BP1 is required for class switch recombination. J Cell Biol (2004) 3.57
PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol (2010) 3.51
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol (2007) 3.50
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res (2013) 3.48
Solid renal tumors: an analysis of pathological features related to tumor size. J Urol (2003) 3.48
B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity (2003) 3.47
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer (2003) 3.33
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res (2003) 3.25
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res (2007) 3.23
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood (2010) 3.21
USP10 regulates p53 localization and stability by deubiquitinating p53. Cell (2010) 3.17
The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol (2013) 3.11
Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer (2006) 3.08
Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol (2010) 3.06
Diabetes mellitus and hypertension associated with shock wave lithotripsy of renal and proximal ureteral stones at 19 years of followup. J Urol (2006) 3.05
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood (2007) 3.00
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood (2007) 2.93
Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res (2003) 2.91
Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood (2009) 2.91
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81
Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer (2014) 2.77
Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol (2012) 2.73
Robotic-assisted laparoscopic partial nephrectomy: technique and initial clinical experience with DaVinci robotic system. Urology (2004) 2.68
Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med (2003) 2.66
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol (2011) 2.63
Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol (2004) 2.61